黑料网

A healthcare telementoring program housed at The Neuro and supported by the is expanding its reach after achieving designation as an ECHO Superhub. Under the direction of Julie Scorah, PhD, this milestone ensures that specialized knowledge reaches underserved communities.

A healthcare telementoring program housed at The Neuro and supported by the is expanding its reach after achieving designation as an ECHO Superhub. Under the direction of Julie Scorah, PhD, this milestone ensures that specialized knowledge reaches underserved communities.

A healthcare telementoring program housed at The Neuro and supported by the is expanding its reach after achieving designation as an ECHO Superhub. Under the direction of Julie Scorah, PhD, this milestone ensures that specialized knowledge reaches underserved communities.

A healthcare telementoring program housed at The Neuro and supported by the is expanding its reach after achieving designation as an ECHO Superhub. Under the direction of Julie Scorah, PhD, this milestone ensures that specialized knowledge reaches underserved communities.

A healthcare telementoring program housed at The Neuro and supported by the is expanding its reach after achieving designation as an ECHO Superhub. Under the direction of Julie Scorah, PhD, this milestone ensures that specialized knowledge reaches underserved communities.

A healthcare telementoring program housed at The Neuro and supported by the is expanding its reach after achieving designation as an ECHO Superhub. Under the direction of Julie Scorah, PhD, this milestone ensures that specialized knowledge reaches underserved communities.

A healthcare telementoring program housed at The Neuro and supported by the is expanding its reach after achieving designation as an ECHO Superhub. Under the direction of Julie Scorah, PhD, this milestone ensures that specialized knowledge reaches underserved communities.

Since becoming only the second Alzheimer鈥檚-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD in the last quarter of 2024.

Since becoming only the second Alzheimer鈥檚-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD in the last quarter of 2024.

Since becoming only the second Alzheimer鈥檚-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD in the last quarter of 2024.

Since becoming only the second Alzheimer鈥檚-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD in the last quarter of 2024.

Since becoming only the second Alzheimer鈥檚-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD in the last quarter of 2024.

Since becoming only the second Alzheimer鈥檚-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD in the last quarter of 2024.

Since becoming only the second Alzheimer鈥檚-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD in the last quarter of 2024.

Since becoming only the second Alzheimer鈥檚-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD in the last quarter of 2024.

Since becoming only the second Alzheimer鈥檚-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD in the last quarter of 2024.

Since becoming only the second Alzheimer鈥檚-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD in the last quarter of 2024.

Since becoming only the second Alzheimer鈥檚-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD in the last quarter of 2024.

Since becoming only the second Alzheimer鈥檚-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD in the last quarter of 2024.

听

A project led by Ziv Gan-Or, MD, PhD, at The Neuro (Montreal Neurological Institute-Hospital) of 黑料网 and Martine T茅treault, PhD, at Universit茅 de Montr茅al has received more than $8 million to sequence the genomes of 8,700 people, to map the role of genetics in neurological disorders.